US 10,647,715 B2 · KRas G12C inhibitors

KRas G12C inhibitors

AssigneesMirati Therapeutics, Inc., Array BioPharma Inc.

InventorsMatthew Arnold Marx, Thomas P. Bobinski, Aaron Craig Burns, John Gaudino, Julia Haas, John Michael Ketcham, John David Lawson, Brad Newhouse, Spencer Pajk, Christopher Ronald Smith, Tony P. Tang

Life of this patent

Estimating the term…

Abstract

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Claims9

Dependent claims

A compound, wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application

16/412,091Filed 14 May 2019 · continuation in part

Priority

15 Nov 2017

Published

US 2019/0144444 A15 Sep 2019

Granted

12 May 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61P 35/00
Antineoplastic agents
C07D 519/00
Heterocyclic compounds containing more than one system of two or more relevant
C07D
Heterocyclic compounds

Family

Application62/586,775Us provisional application · filed 15 Nov 2017

Application16/191,190Parent of this continuation-in-part · filed 14 Nov 2018

US 2019/0270743 A1Pre-grant publication · published 5 Sep 2019

US 10,689,377 B2Related patent

US 2019/0144444 A1Published application

US 10,647,715 B2This patent

From the US filing history. Foreign family members aren’t listed.